S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   357.89 (-0.03%)
AAPL   171.04 (+0.21%)
MSFT   315.62 (+0.63%)
META   302.19 (-0.58%)
GOOGL   131.29 (-0.77%)
AMZN   126.61 (+0.50%)
TSLA   249.03 (+1.08%)
NVDA   434.99 (+0.95%)
NIO   8.95 (+0.45%)
BABA   86.97 (+1.67%)
AMD   103.23 (+0.46%)
T   14.96 (-0.33%)
F   12.44 (-0.96%)
MU   67.60 (+3.68%)
CGC   0.79 (-2.78%)
GE   110.32 (-1.80%)
DIS   80.67 (+0.67%)
AMC   8.02 (+2.95%)
PFE   33.06 (+3.02%)
PYPL   58.21 (+0.05%)
NFLX   376.29 (-0.02%)
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Forecast, Price & News

$6.77
0.00 (0.00%)
(As of 01:28 PM ET)
Compare
Today's Range
$6.58
$6.89
50-Day Range
$6.56
$10.62
52-Week Range
$5.77
$18.96
Volume
393,333 shs
Average Volume
830,263 shs
Market Capitalization
$479.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.20

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
347.4% Upside
$30.20 Price Target
Short Interest
Bearish
9.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Aclaris Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$99,994 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.82) to ($1.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

805th out of 970 stocks

Pharmaceutical Preparations Industry

385th out of 454 stocks


ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Price History

ACRS Stock News Headlines

This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Aclaris Therapeutics' (ACRS) Buy Rating Reaffirmed at HC Wainwright
Expert Ratings for Aclaris Therapeutics
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Jefferies Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
Aclaris Therapeutics rises 13% on insider buy
2 Low-Priced Stocks That Could Make You Richer
BTIG Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)
Aclaris Therapeutics (NASDAQ: ACRS)
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
8/07/2023
Today
9/29/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$30.20
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+346.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-86,910,000.00
Net Margins
-337.90%
Pretax Margin
-337.90%

Debt

Sales & Book Value

Annual Sales
$29.75 million
Book Value
$2.96 per share

Miscellaneous

Free Float
66,901,000
Market Cap
$479.25 million
Optionable
Optionable
Beta
0.65

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Neal S. Walker D.O. (Age 53)
    Co-Founder & Chairman
    Comp: $955.69k
  • Dr. Douglas J. Manion Frcp(C) (Age 62)
    M.D., CEO, Pres & Director
    Comp: $572.16k
  • Dr. Joseph Monahan Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $600.02k
  • Dr. Gail Cawkwell M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $371.17k
  • Mr. Kevin Balthaser (Age 36)
    Chief Financial Officer
  • Mr. Robert A. Doody Jr.
    VP of Investor Relations
  • Mr. Matthew Rothman J.D.
    Gen. Counsel & Corp. Sec.
  • Ms. Jill Conwell
    Chief People Officer
  • Mr. Gary A. DeCrescenzo
    Sr. VP of Pharmaceutical R&D
  • Dr. Jon Jacobsen Ph.D.
    Sr. VP of Chemistry













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 1 year price targets for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $20.00 to $43.00. On average, they anticipate the company's share price to reach $30.20 in the next twelve months. This suggests a possible upside of 346.1% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS shares have decreased by 57.0% and is now trading at $6.77.
View the best growth stocks for 2023 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,520,000 shares, an increase of 14.4% from the August 31st total of 5,700,000 shares. Based on an average daily trading volume, of 715,100 shares, the days-to-cover ratio is currently 9.1 days.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its earnings results on Monday, August, 7th. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.03. The biotechnology company earned $1.90 million during the quarter, compared to analyst estimates of $1.90 million. Aclaris Therapeutics had a negative net margin of 337.90% and a negative trailing twelve-month return on equity of 54.43%. The company's revenue was up 26.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.31) earnings per share.

What ETFs hold Aclaris Therapeutics' stock?
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $6.77.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $479.25 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -